brivaracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 24 Diseases   12 Trials   12 Trials   871 News 


«12345678910111213»
  • ||||||||||  brivaracetam / Generic mfg.
    Journal:  Sustained seizure freedom with adjunctive brivaracetam in patients with focal-onset seizures. (Pubmed Central) -  May 10, 2022   
    Sustained seizure response was reached by 383 (38.5%) patients: 236/383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by day-1, 94/383 (24.5%) by month-4, and 53/383 (13.8%) by month-7 up to month-12. Adjunctive BRV was associated with sustained seizure frequency reduction since the first day of treatment in a subset of patients with uncontrolled focal epilepsy.
  • ||||||||||  brivaracetam / Generic mfg.
    Journal:  Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants. (Pubmed Central) -  Apr 23, 2022   
    Brivaracetam was well tolerated.Because response to brivaracetam in epilepsy is related to exposure (AUC), no dose adjustment is warranted when switching from oral to intravenous dosing. However, investigations are needed to assess the safety and tolerability of intravenous administration in Japanese patients with epilepsy.
  • ||||||||||  brivaracetam / Generic mfg.
    Review, Journal:  Brivaracetam add-on therapy for drug-resistant epilepsy. (Pubmed Central) -  Apr 22, 2022   
    Consequently, the findings of this review are mainly applicable to adult patients with drug-resistant focal epilepsy. Future research should focus on investigating the tolerability and efficacy of brivaracetam during longer-term follow-up, as well as assess the efficacy and tolerability of add-on brivaracetam in managing other types of seizures and in other age groups.
  • ||||||||||  brivaracetam / Generic mfg.
    Journal:  Rise of the Machines? Predicting Brivaracetam Response Using Machine Learning. (Pubmed Central) -  Apr 22, 2022   
    Future research should focus on investigating the tolerability and efficacy of brivaracetam during longer-term follow-up, as well as assess the efficacy and tolerability of add-on brivaracetam in managing other types of seizures and in other age groups. No abstract available
  • ||||||||||  Briviact (brivaracetam) / UCB
    Clinical, Journal:  Efficacy of Brivaracetam in children with epilepsy. (Pubmed Central) -  Mar 30, 2022   
    Overall, long-term adjunctive BRV was generally well tolerated and reduced the frequency of FBTCS in adults, with 22.8% of patients (who completed ≥ 1 year of treatment) not reporting any FBTCS during the first year from the first day of BRV treatment. BRV appears to be an effective, safe, and well-tolerated AED in children with refractory epilepsy.
  • ||||||||||  Clinical, Journal:  Epilepsy in adults with neurodevelopmental disability - what every neurologist should know. (Pubmed Central) -  Mar 29, 2022   
    Seizures with a co-morbid NDD should be considered as a collective complex clinical presentation and not discrete conditions. This seminar was co-designed, co-produced and co-authored by an expert by experience and includes case studies and a video to highlight what can go wrong and how it can be avoided.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Clinical, Review, Journal:  Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. (Pubmed Central) -  Mar 19, 2022   
    Although NMAs cannot replace direct comparisons, they may support physicians in clinical decision making. Patients receiving FDA-RDMD of cenobamate were more likely to have ≥50% seizure reduction compared with FDA-RDMD of the seven assessed ASMs and branded ASMs, without an increase in treatment discontinuation due to TEAEs.
  • ||||||||||  Briviact (brivaracetam) / UCB
    Clinical, Journal, HEOR, Real-world evidence:  Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). (Pubmed Central) -  Mar 18, 2022   
    Patients receiving FDA-RDMD of cenobamate were more likely to have ≥50% seizure reduction compared with FDA-RDMD of the seven assessed ASMs and branded ASMs, without an increase in treatment discontinuation due to TEAEs. The BRIVAFIRST provided real-world evidence on the effectiveness of BRV in patients with focal epilepsy irrespective of LEV history and concomitant ASMs, and suggested favourable therapeutic combinations.
  • ||||||||||  pregabalin / Generic mfg., gabapentin / Generic mfg.
    Safety Profiles of Second-Generation Antiseizure Medications: A Pharmacovigilance Study (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2885;    
    This comprehensive analysis of postmarketing data from the FDA Adverse Event Database shows differences in safety profiles between new generation ASMs. Rigorous post-market surveillance and further research is required to better understand the long-term safety of these drugs to make informed clinical decisions.
  • ||||||||||  everolimus / Generic mfg., carbamazepine / Generic mfg.
    Everolimus for Treatment of Refractory Seizures in Tuberous Sclerosis (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2884;    
    She was on Phenytoin and brivaracetam when she presented to us and was experiencing 5-6 seizures per month... Everolimus has been shown to be of tremendous benefit to Tuberous Sclerosis patients, both in reducing tumor size as well as a treatment for intractable epilepsy. Physicians should consider the use of Everolimus as an adjunctive treatment for refractory epilepsy in patients with Tuberous sclerosis to help decrease seizure burden and improve quality of life.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Cenobamate for Uncontrolled Focal Seizures in Patients Living in a Group Home or With a Developmental Disability (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2730;    
    Patients living in a group home or with developmental disability experienced substantial reduction in focal seizure frequency and high responder rates, including seizure freedom, with adjunctive cenobamate. Treatment was well tolerated; AEs were often mitigated or resolved following reduction of concomitant ASMs.
  • ||||||||||  Briviact (brivaracetam) / UCB
    Real-world Study of Brivaracetam in the United States () -  Mar 6, 2022 - Abstract #AAN2022AAN_1569;    
    Main eligibility criteria included a history of focal seizures, age ≥16 years, and lifetime history or concomitant use of ≥1 of four specific antiseizure medications (ASMs): levetiracetam/lamotrigine/oxcarbazepine/carbamazepine. BRV demonstrated long-term effectiveness in this US observational study.
  • ||||||||||  lenalidomide / Generic mfg.
    Journal:  Ligand Enabled Pd(II)-Catalyzed γ-C(sp)-H Lactamization of Native Amides. (Pubmed Central) -  Mar 3, 2022   
    This protocol features the use of N-acyl amino acids, which serve as both the directing group and cyclization partner, practical and environmentally benign tert-butyl hydrogen peroxide (TBHP) as the sole bystanding oxidant, and a broad substrate scope. The utility of this protocol was demonstrated through the two-step syntheses of a lenalidomide analog and brivaracetam from readily available carboxylic acids and amino acids.
  • ||||||||||  brivaracetam / Generic mfg.
    Trial completion:  Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) -  Feb 8, 2022   
    P3,  N=257, Completed, 
    Overall, BRV was well-tolerated as long-term adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease, with improvements in focal seizure frequency maintained over time. Active, not recruiting --> Completed
  • ||||||||||  Briviact (brivaracetam) / UCB
    Review, Journal:  Synthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug. (Pubmed Central) -  Feb 1, 2022   
    Given its efficiency in limiting the progression of epilepsy, this drug has drawn considerable attention of researchers to devise novel routes of its synthesis. The present review encapsulates the reported literature on synthetic strategies for brivaracetam, which will assist medicinal chemists in the further progress of its synthesis.
  • ||||||||||  Briviact (brivaracetam) / UCB
    Ligand Enabled Pd(II)-Catalyzed γ-C(sp3)−H Lactamization of Native Amides (Room 4 (San Diego Convention Center)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_7410;    
    γ-Lactams form important structural cores of a range of medicinally-relevant natural products and clinical drugs, principal examples being the new generation of immunomodulatory imide drugs (IMiDs) and the brivaracetam family...Herein we report a novel pyridone ligand enabled Pd(II)-catalyzed γ-C(sp3)−H lactamization of native amides, enabling the convenient synthesis of γ-lactams, isoindolinones, and imidazolidinones. This protocol features 1) the use of native amides, which serve as both the directing group and cyclization partner, 2) practical and inexpensive tert-butyl hydrogen peroxide (TBHP) as the sole bystanding oxidant, and 3) a broad substrate scope.